A Study of Fibrinogen Turnover in Classical Hemophilia and Congenital Afibrinogenemia
Aaron R. Rausen, André Cruchaud, Campbell W. McMillan, David Gitlin
Abstract
Open-access reader
Aaron R. Rausen, André Cruchaud, Campbell W. McMillan, David Gitlin
Abstract
Open-access reader
Abstract The rate of disappearance from the plasma of intravenously administered I131-labeled fibrinogen was studied in six patients with classical hemophilia and in one patient with congenital afibrinogenemia. The six patients with hemophilia had radioiodinated fibrinogen half-lives ranging from 2.8 to 3.6 days, while the patient with congenital afibrinogenemia had a labeled fibrinogen half-life of 3.0 days. These results compare favorably with fibrinogen turnover rates measured in normal adults by others and were similar to the normal fibrinogen turnover rate determined in the patient with congenital afibrinogenemia in a previous study. This failure to demonstrate a prolongation of survival of fibrinogen in patients with hemophilia suggests that in vivo clotting, if it occurs at all normally, is not a major factor in the turnover of fibrinogen.
OpenAlex reports 38 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract The rate of disappearance from the plasma of intravenously administered I131-labeled fibrinogen was studied in six patients with classical hemophilia and in one patient with congenital afibrinogenemia. The six patients with hemophilia had radioiodinated fibrinogen half-lives ranging from 2.8 to 3.6 days, while the patient with congenital afibrinogenemia had a labeled fibrinogen half-life of 3.0 days. These results compare favorably with fibrinogen turnover rates measured in normal adults by others and were similar to the normal fibrinogen turnover rate determined in the patient with congenital afibrinogenemia in a previous study. This failure to demonstrate a prolongation of survival of fibrinogen in patients with hemophilia suggests that in vivo clotting, if it occurs at all normally, is not a major factor in the turnover of fibrinogen.
Key concepts: Afibrinogenemia, Fibrinogen, Medicine, Coagulopathy, Internal medicine, Surgery